149 related articles for article (PubMed ID: 36860272)
1. Antibiotic Susceptibility Patterns for Carbapenem-Resistant Enterobacteriaceae.
Armin S; Fallah F; Karimi A; Karbasiyan F; Alebouyeh M; Rafiei Tabatabaei S; Rajabnejad M; Mansour Ghanaie R; Fahimzad SA; Abdollahi N; Khodaei H; Azimi L
Int J Microbiol; 2023; 2023():8920977. PubMed ID: 36860272
[TBL] [Abstract][Full Text] [Related]
2. Study on MICs of Tigecycline in Clinical Isolates of Carbapenem Resistant Enterobacteriaceae (CRE) at a Tertiary Care Centre in North India.
Khare V; Gupta P; Haider F; Begum R
J Clin Diagn Res; 2017 Mar; 11(3):DC18-DC21. PubMed ID: 28511383
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
Jia P; Zhu Y; Zhang H; Cheng B; Guo P; Xu Y; Yang Q
BMC Microbiol; 2022 Oct; 22(1):234. PubMed ID: 36182895
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and Genotypic Characterization of Carbapenem-resistant Enterobacteriaceae: Data From a Longitudinal Large-scale CRE Study in China (2012-2016).
Wang Q; Wang X; Wang J; Ouyang P; Jin C; Wang R; Zhang Y; Jin L; Chen H; Wang Z; Zhang F; Cao B; Xie L; Liao K; Gu B; Yang C; Liu Z; Ma X; Jin L; Zhang X; Man S; Li W; Pei F; Xu X; Jin Y; Ji P; Wang H
Clin Infect Dis; 2018 Nov; 67(suppl_2):S196-S205. PubMed ID: 30423057
[TBL] [Abstract][Full Text] [Related]
5. Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center.
Kulengowski B; Burgess DS
Pathog Dis; 2019 Jun; 77(4):. PubMed ID: 31365075
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of carbapenem-resistant
Yan WJ; Jing N; Wang SM; Xu JH; Yuan YH; Zhang Q; Li AL; Chen LH; Zhang JF; Ma B; Ma Q; Li Y
J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33587030
[No Abstract] [Full Text] [Related]
7. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility to 19 agents other than β-lactams among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
Mischnik A; Baumert P; Hamprecht A; Rohde AM; Peter S; Feihl S; Knobloch J; Gölz H; Kola A; Obermann B; Querbach C; Willmann M; Gebhardt F; Tacconelli E; Gastmeier P; Seifert H; Kern WV;
J Antimicrob Chemother; 2017 May; 72(5):1359-1363. PubMed ID: 28108677
[TBL] [Abstract][Full Text] [Related]
9. Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistant
El-Mahallawy HA; El Swify M; Abdul Hak A; Zafer MM
Ann Med; 2022 Dec; 54(1):1-9. PubMed ID: 36373970
[TBL] [Abstract][Full Text] [Related]
10. A Comparative
Singh S; Sahu C; Patel SS; Singh A; Yaduvanshi N
Indian J Crit Care Med; 2020 Dec; 24(12):1213-1217. PubMed ID: 33446975
[TBL] [Abstract][Full Text] [Related]
11. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
[TBL] [Abstract][Full Text] [Related]
12. Rapid Increase in Prevalence of Carbapenem-Resistant Enterobacteriaceae (CRE) and Emergence of Colistin Resistance Gene
Li Y; Sun QL; Shen Y; Zhang Y; Yang JW; Shu LB; Zhou HW; Wang Y; Wang B; Zhang R; Wang S; Shen Z
J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29386265
[TBL] [Abstract][Full Text] [Related]
13. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.
Livermore DM; Warner M; Mushtaq S; Doumith M; Zhang J; Woodford N
Int J Antimicrob Agents; 2011 May; 37(5):415-9. PubMed ID: 21429716
[TBL] [Abstract][Full Text] [Related]
14. Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections.
Bhowmick T; Weinstein MP
Infect Dis Ther; 2020 Dec; 9(4):757-767. PubMed ID: 33017041
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility profile, resistance mechanisms & efficacy ratios of fosfomycin, nitrofurantoin & colistin for carbapenem-resistant
Amladi AU; Abirami B; Devi SM; Sudarsanam TD; Kandasamy S; Kekre N; Veeraraghavan B; Sahni RD
Indian J Med Res; 2019 Feb; 149(2):185-191. PubMed ID: 31219082
[TBL] [Abstract][Full Text] [Related]
16. Carbapenem-Resistant Enterobacteriaceae Infections: Taiwan Aspects.
Jean SS; Lee NY; Tang HJ; Lu MC; Ko WC; Hsueh PR
Front Microbiol; 2018; 9():2888. PubMed ID: 30538692
[TBL] [Abstract][Full Text] [Related]
17. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
[TBL] [Abstract][Full Text] [Related]
18. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
Wenzler E; Scoble PJ
Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
[TBL] [Abstract][Full Text] [Related]
20. [Microbiological profiles of pathogens causing nosocomial bacteremia in 2011, 2013 and 2016].
Wang X; Zhao C; Li H; Chen H; Jin L; Wang Z; Liao K; Zeng J; Xu X; Jin Y; Su D; Liu W; Hu Z; Cao B; Chu Y; Zhang R; Luo Y; Hu B; Wang H
Sheng Wu Gong Cheng Xue Bao; 2018 Aug; 34(8):1205-1217. PubMed ID: 30152206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
